Pharmaceutical giant Merck is boosting its U.S. investments to more than $70 billion, according to Reuters.
The move underscores its commitment to strengthening domestic manufacturing and research. The company already has major operations throughout Montco. It plans to expand biologics and small-molecule production and enhance R&D capabilities across its U.S. network.
Merck’s expansion includes construction of a $3 billion pharmaceutical plant in Virginia, expected to generate 500 jobs, as well as a $3.5 billion investment at its Rahway, N.J. headquarters. The company has also opened a $1 billion facility in North Carolina and committed $1 billion to a new Delaware site to manufacture biologics, including the cancer drug Keytruda.
The company’s continued growth signals long-term stability and potential job opportunities for Montco’s thriving life-sciences sector. While the latest announcement does not cite specific projects in Montgomery County, Merck’s West Point site remains one of the firm’s largest vaccine manufacturing facilities worldwide.
To learn more about Merck’s national expansion and what it means for local operations, visit Reuters.
